Abstract: An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.

Abstract: Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.

Abstract: Apparatus and methods for treatment of an internal cavity are provided. The internal cavity is coated with a treatment solution. The treatment solution can include a solidifiable matrix with or without a drug or combination of drugs incorporated therein, or a drug solution without a solidifiable matrix. The treatment solution is coated onto at least a portion of the internal cavity, and acts as a slow-release drug delivery system.

Abstract: The subject invention pertains to materials and methods for stopping or decreasing the blood flow from an open wound or medical or surgical procedure. Compositions of the invention comprise a salt form of a cross-linked polyacrylic acid. In one embodiment, the composition comprises a sodium salt of a polyacrylic acid. Compositions of the invention can also optionally comprise one or more different salt ferrates, and/or a cationic exchanger resins, and/or a silver compound. In an exemplified embodiment, a composition of the invention comprises sodium polyacrylate provided in a dry powdered form. Polyacrylate compositions of the invention can be applied directly to a wound or treatment site, or they can be incorporated into a wound dressing, such as a bandage. The clot or scab formed at a wound or treatment site treated with the present invention is extremely elastic and exhibits considerable tensile strength when stretched to the breaking point.

Abstract: The present invention relates to pharmaceutical compositions in the form of a gel for controlled- or sustained-release of a pharmaceutically active agent and to methods for treating or preventing a condition in an animal by administering to an animal in need thereof the pharmaceutical compositions. One particular type of condition for which the pharmaceutical compositions are useful is a microbial infection, e.g., of the skin, ear, or eye, especially for veterinary applications.

Abstract: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.

Abstract: There is provided a new aqueous temperature responsive delivery system made with a temperature responsive polymer and a bioadhesive which is intrinsically cationic. This system may also have an effective amount of a treating agent, which may be a medical or cosmetic agent. The bioadhesive, temperature responsive delivery system is useful in delivering moisturizers or pharmaceutically active agents to the user in controlled release manners, through the tissues in a body cavity.

Abstract: A spinning solution composition which provides regenerated silk fiber that exhibits a strength and elongation close to those of natural silk fiber, is rapidly degradable in vivo, and can be caused to have ability to gradually release a drug to prevent inflammation; a process for producing such regenerated silk fiber by use of the composition; and regenerated silk fiber obtained through the process.

Abstract: The invention provides photocrosslinkable, injectable, biodegradable oligo(poly(ethylene glycol) fumarate) (OPF) hydrogels made from the photopolymerization of an OPF macromer with UV light and a photoinitiator. Hydrogels with varying mechanical properties and water content can be made with changes in macromer and crosslinking agent concentration in a precursor solution. The biodegradable OPF hydrogels can be injected as a fluid into a bodily defect of any shape, may incorporate various therapeutic agents, e.g., cells and/or growth factors, and may be implanted via minimally invasive arthroscopic techniques.

Abstract: The present invention is related to surfactant-based formulations comprising the polyelectrolytes and blends of such polyelectrolytes with non-cellulosic cationic polysaccharide polymers. The surfactant-based formulations exhibit improved clarity of the resulting formulations, their improved conditioning of keratin substrates, textile substrates, and hard-surface substrates, their improved deposition of dispersed phase materials onto keratin substrates, textile substrates, and hard-surface substrates, their improved lather performance, and their improved rheology in applications such as personal care and household care products and textile applications.

Abstract: Compositions comprising the peroxisome proliferator-activated receptor alpha (PPAR?)-ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC) are disclosed. These compositions may be used for the prophylaxis and treatment of PPAR?-related liver disorders including, but not necessarily limited to, fatty liver disease, to lower lipid and triglyceride levels, and to increase high density lipoprotein levels in animals. Foods modified with 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1GPC) may be used to improve the metabolism of animals.

Abstract: Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.

Abstract: The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.

Abstract: A biocide composition, comprising 2-methylisothiazolin-3-one as a biocidal active ingredient and at least one further biocidal active ingredient, as an additive to materials capable of being attacked by harmful microorganisms, wherein the composition comprises a pyrithione as the further biocidal active ingredient.

Abstract: An applicator for dispensing two separate tissue adhesives includes a generally elongate body having two distinct interior regions, each containing one of the two tissue adhesives. Hinged levers associated with each region selectively force the expulsion of the adhesive from the end portions of the applicator in response to application of force by the operator.

Abstract: The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof.

Abstract: Diagnosing or treating a human ear includes transporting a conjugated nanoparticle or a magnetically responsive nanoparticle into a human's middle or inner ear. Otologic nanophoresis includes electrically, magnetically or electromagnetically driving a nanoparticle through a membrane of the ear, including a tympanic membrane, a round window membrane, an oval window membrane, or a circulatory membrane. An otologic diagnostic device includes a nanoparticle conjugated with a material selected from the group consisting of lipids, proteins, growth factors, growth hormones, antioxidants, free radical scavengers, steroid preparations, and metabolically active substances; an otologic therapeutic device includes the same categories of substances and chemotherapeutic drugs. Another otologic composition includes a nanoparticle conjugated with a substance perceptible to magnetic resonance imaging.

Abstract: The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and/or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.

Abstract: Pharmaceutical compositions comprising fluvastatin, HPMC and optionally other pharmaceutical excipients which are colour-stable upon prolonged periods of storage.

Abstract: A composition comprising mineral water and a chelating agent present in an amount sufficient to maintain all of the minerals in the water in solution. The mineral water is preferably obtained from Mount Clemens, Mich., US, and is preferably chelated with an ammonium and/or a sodium salt of an acid selected from the group consisting of ethylenediaminetetraacetic acid, nitrilotetraacetic acid, ?-alaninediacetic acid, ethylenediaminosuccinic acid, aminotrimethylenephosphoric acid, serinediaacetic acid, asparaginediacetic acid, methylgylcinediacetic acid and mixtures thereof. The resultant chelated mineral water may be combined with a cosmetically acceptable skin-conditioning agent and a cosmetically acceptable topical carrier, thereby resulting in a cosmetic composition that will confer beneficial effects on the skin, e.g., softening, hydrating and healing effects.